Aims and Scope

Trends in Pharmaceutical Biotechnology (TPB) is an international, peer-reviewed, open-access journal publishing original research articles, reviews, and short communications on the biotechnological development, engineering, and translational evaluation of pharmaceutical products. The journal's focus is the science and technology that connect a biological or chemical drug candidate to a deliverable therapeutic product — spanning molecular design, bioprocessing, formulation, and translational proof-of-concept.

TPB welcomes submissions in the following areas:

1. Biopharmaceutical Design and Molecular Engineering Design, synthesis, and characterization of novel therapeutic compounds, including metal-based and coordination-chemistry drug candidates; protein and antibody engineering; recombinant therapeutic proteins; enzyme and biocatalyst engineering; structure–activity relationship and molecular docking studies supporting a biotechnological drug candidate.

2. Bioprocessing and Biomanufacturing Fermentation and expression-system optimization; inclusion-body refolding and downstream purification; host-cell protein and impurity characterization; analytical platforms for biologic drug substances; scale-up, process analytical technology, and quality-by-design in biopharmaceutical manufacturing.

3. Drug Delivery and Nanobiotechnology Nanoparticle, liposomal, polymeric (e.g., PLGA), and lipid-nanoparticle drug-delivery systems; PEGylation and other bioconjugation strategies; targeted and stimuli-responsive delivery platforms; nanotoxicology and formulation stability of biotechnological products.

4. Gene, Cell, and Viral-Vector Therapeutics Gene therapy vectors, oncolytic viruses, RNA-based therapeutics, and cell-based and immunotherapy platforms; preclinical and clinical-trial evidence for biotechnology-derived therapeutics, including biologics, gene therapies, and cytokine-engineered agents.

5. Precision Pharmacotherapy and Pharmacogenomics Biomarker- and genotype-guided drug selection and dosing frameworks; drug repurposing centered on molecular and mechanistic rationale with biomarker-anchored patient stratification.

6. Translational and Preclinical Evaluation In vitro, in vivo, and early-phase clinical (phase 1–3) studies whose primary contribution is the evaluation of a biotechnological product, platform, or delivery system.

TPB does not publish studies whose primary contribution is a general clinical-practice question unconnected to a specific biotechnological product or platform — for example, comparative dosing or peri-operative management cohort studies, general epidemiological or predictive-risk-index studies, or clinical guideline syntheses without a biotechnology-development component.

The journal serves researchers, clinicians, and industry professionals working at the interface of biotechnology and pharmaceutical sciences, and aims to accelerate the translation of biotechnological innovation into safe, effective, and accessible therapeutics.